Accelerated vs. Standard Continuous Renal Replacement Therapy for Patients With Cardiogenic Shock Undergoing Veno-arterial ExtraCorporeal Membrane Oxygenator

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 408 participants.

Also called NCT06696235

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 408 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06696235
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06696235. Randomized; no masking; primary purpose treatment. Start 2024-12-31 (actual); primary completion 2028-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Accelerated vs. Standard Continuous Renal Replacement Therapy for Patients With Cardiogenic Shock Undergoing Veno-arterial ExtraCorporeal Membrane Oxygenator
Acronym
REDUCE-ECMO
Condition
Cardiogenic Shock
Intervention (Device)
Early initiation of continuous renal replacement therapy
Intervention (Device)
Standard initiation of continuous renal replacement therapy
Lead sponsor
Samsung Medical Center (class: other)

Record details

Record id
cardio:ct-nct06696235
Content hash
5d4cec9f52bf62eafc5027aa100ee491f4a0bc4f57f8e6f66d9652527cad1214